CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
Is reduction from adalimumab 80mg to 40mg sufficient for maintenance of remission in patients with Crohn's disease?
DOI 10.1055/s-2007-988323
Bibliografische Angaben
Nachweis in CareLit
Autor:innenM Jürgens, J Seiderer, S Brand, S Pfennig, B Göke, T Ochsenkühn
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe09/2007
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Introduction: The human monoclonal anti-TNF-α antibody adalimumab (Humira, Abbott Laboratories Chicago) has become a promising treatment option in refractory Crohn's disease. In a recently published study (Aliment Pharmacol Ther 2007; 25:787–96), we induced remission with 160mg adalimumab subcutaneously in week 0 and maintained remission with 80mg every other week (eow) in 10 of 16 patients with moderate to severe C…
Zitieren
Zitierempfehlung
M Jürgens, J Seiderer, S Brand, S Pfennig, B Göke, T Ochsenkühn (2007) Is reduction from adalimumab 80mg to 40mg sufficient for maintenance of remission in patients with Crohn's disease?. Zeitschrift für Gastroenterologie (09). https://doi.org/10.1055/s-2007-988323
Mit CareLit weiterarbeiten